Avadel Pharmaceuticals plc

13.77+0.0200+0.15%Vol 1.19M1Y Perf 64.67%
Dec 6th, 2023 16:00 DELAYED
BID12.50 ASK14.96
Open13.75 Previous Close13.75
Pre-Market- After-Market13.75
 - -  -0.02 -0.15%
Target Price
12.35 
Analyst Rating
Strong Buy 1.11
Potential %
-10.31 
Finscreener Ranking
     31.57
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     33.52
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     19.02
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
71.82 
Earnings Rating
Strong Sell
Market Cap1.24B 
Earnings Date
8th Nov 2023
Alpha0.04 Standard Deviation0.28
Beta1.54 

Today's Price Range

13.4514.02

52W Range

5.9216.85

5 Year PE Ratio Range

-7.60231.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
19.32%
1 Month
32.66%
3 Months
5.88%
6 Months
-5.88%
1 Year
64.67%
3 Years
102.80%
5 Years
415.73%
10 Years
-

TickerPriceChg.Chg.%
AVDL13.770.02000.15
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
2.60
2.70
0.68
2.63
-7.40
Leverage Ratio 14.70
ProfitabilityValueIndustryS&P 500US Markets
67.50
9.70
24.00
-33.40
-46.60
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-33.41
-13.06
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.35-0.41-17.14
Q02 2023-0.39-0.70-79.49
Q01 2023-0.37-0.48-29.73
Q04 2022-0.30-0.44-46.67
Q03 2022-0.22-0.33-50.00
Q02 2022-0.41-0.50-21.95
Q01 2022-0.44-0.45-2.27
Q04 2021-0.42-0.389.52
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.30-11.11Negative
12/2023 FY-1.86-4.49Negative
3/2024 QR-0.26-23.81Negative
12/2024 FY-0.49-32.43Negative
Next Report Date-
Estimated EPS Next Report-0.35
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.19M
Shares Outstanding89.81K
Shares Float80.11M
Trades Count8.04K
Dollar Volume16.39M
Avg. Volume689.70K
Avg. Weekly Volume710.53K
Avg. Monthly Volume770.87K
Avg. Quarterly Volume587.71K

Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock closed at 13.77 per share at the end of the most recent trading day (a 0.15% change compared to the prior day closing price) with a volume of 1.19M shares and market capitalization of 1.24B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50 people. Avadel Pharmaceuticals plc CEO is Gregory J. Divis.

The one-year performance of Avadel Pharmaceuticals plc stock is 64.67%, while year-to-date (YTD) performance is 92.32%. AVDL stock has a five-year performance of 415.73%. Its 52-week range is between 5.92 and 16.85, which gives AVDL stock a 52-week price range ratio of 71.82%

Avadel Pharmaceuticals plc currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 7.63, a price-to-sale (PS) ratio of 42.02, a price to cashflow ratio of 16.60, a PEG ratio of -, a ROA of -71.62%, a ROC of -67.44% and a ROE of -370.73%. The company’s profit margin is -46.60%, its EBITDA margin is 24.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Avadel Pharmaceuticals plc, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Avadel Pharmaceuticals plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Avadel Pharmaceuticals plc is Strong Buy (1.11), with a target price of $12.35, which is -10.31% compared to the current price. The earnings rating for Avadel Pharmaceuticals plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Avadel Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Avadel Pharmaceuticals plc has a Buy technical analysis rating based on Technical Indicators (ADX : 14.56, ATR14 : 0.77, CCI20 : 251.96, Chaikin Money Flow : -0.01, MACD : 0.54, Money Flow Index : 77.07, ROC : 28.26, RSI : 72.49, STOCH (14,3) : 94.92, STOCH RSI : 1.00, UO : 66.24, Williams %R : -5.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Avadel Pharmaceuticals plc in the last 12-months were: Divis Greg (Buy at a value of $132 000), Ende Eric (Buy at a value of $181 090), Linda Palczuk (Buy at a value of $36 900)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.11
Strong Buy
1.11
Strong Buy
1.11

Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

CEO: Gregory J. Divis

Telephone: +353 14851200

Address: 10 Earlsfort Terrace, Dublin D02 T380, , IE

Number of employees: 50

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

60%40%

 

TipRanks News for AVDL

Wed, 04 Oct 2023 11:50 GMT Avadel Pharmaceuticals added to Conviction List at Needham

- TipRanks. All rights reserved.

News

Stocktwits